Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th.

Minerva Neurosciences Trading Up 1.7 %

Minerva Neurosciences stock opened at $2.36 on Friday. Minerva Neurosciences has a 1-year low of $2.26 and a 1-year high of $13.49. The firm has a market capitalization of $16.50 million, a price-to-earnings ratio of -0.53 and a beta of 0.18. The firm has a 50 day simple moving average of $2.64 and a 200 day simple moving average of $2.80.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, equities research analysts forecast that Minerva Neurosciences will post -2.26 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.